文献速递前列腺癌

西班牙裔前列腺癌男性的胚系变异

Germline alterations among Hispanic men with prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-02-28

该研究回顾性分析两个队列:一个多中心队列纳入17256名接受胚系检测的男性,另一个单中心队列纳入2018至2020年间所有符合检测条件的男性。结果显示西班牙裔与NHW男性的致病性/可能致病性胚系变异率无显著差异,但西班牙裔男性的意义未明变异率显著更高。作者认为西班牙裔前列腺癌男性应像NHW男性一样接受胚系检测。

要点

  • 多中心队列中,西班牙裔男性P/LP胚系变异率为7.1%,NHW男性为9.7%,差异无统计学显著(p=0.058)。
  • 西班牙裔男性VUS率显著高于NHW男性(21.5% vs. 16.6%,p=0.005)。
  • 单中心队列中,西班牙裔与NHW男性的P/LP变异率无显著差异(14.7% vs. 12.2%,p=0.77),但西班牙裔VUS率显著更高(20.6% vs. 7.2%,p=0.047)。

核心结论

  • 本队列中西班牙裔与NHW男性的P/LP胚系变异率相似,但西班牙裔男性的VUS率显著更高,作者认为这是少数族群检测不足的结果。
  • 这些数据支持西班牙裔前列腺癌男性应像NHW男性一样接受胚系检测。

研究设计与样本

  • 回顾性分析两个独立队列:一个多中心队列纳入17256名在CLIA认证实验室接受胚系检测的男性,一个单中心队列纳入2018至2020年间所有符合胚系检测条件的男性。
  • 计算P/LP变异和VUS的比例,使用Fisher精确检验比较组间差异,并采用多因素逻辑回归调整人口学和临床因素以分析与胚系检测相关的因素。

主要发现

  • 多中心队列中,自我报告为西班牙裔男性的P/LP胚系变异率为7.1%,自我报告为NHW男性为9.7%,差异无统计学显著(p=0.058)。
  • 多中心队列中,西班牙裔男性的VUS率显著高于NHW男性(21.5% vs. 16.6%,p=0.005)。
  • 单中心队列中,136名西班牙裔患者符合检测条件,其中34名接受了胚系检测(26.1%,N=34/136)。
  • 单中心队列中,接受胚系检测的西班牙裔患者P/LP变异率与NHW患者无显著差异(14.7% vs. 12.2%,p=0.77)。
  • 单中心队列中,西班牙裔患者的VUS率显著高于NHW患者(20.6% vs. 7.2%,p=0.047)。

临床怎么用

  • 作者认为,西班牙裔前列腺癌男性应像NHW男性一样接受胚系检测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Little is known about the true rate of pathogenic (P)/likely pathogenic (LP) germline alterations in Hispanic men with prostate cancer as most studies analyzing the prevalence of P/LP germline alterations were performed in a largely non-Hispanic white population (NHW). METHODS: We performed a retrospective analysis of two separate cohorts of men with prostate cancer: (1) a multicenter cohort of 17,256 men who underwent germline testing in a CLIA-certified laboratory and (2) a single-center cohort of all men eligible for germline testing between 2018 and 2020. The proportions of P/LP alterations and variants of uncertain significance (VUS) were computed. Fisher's exact test was used to compare germline alteration rates for significance. A multivariate logistic regression was performed adjusting for demographic and clinical factors to examine factors associated with germline testing. RESULTS: In the multicenter cohort, the rate of P/LP germline alterations among self-reported Hispanic men was 7.1%, which was lower than self-reported NHW men (9.7% vs. 7.1%, p = 0.058), but was not statistically significant. The VUS rate was significantly higher among the Hispanic cohort (21.5% vs. 16.6%, p = 0.005). In the single-center cohort, 136 Hispanic patients were eligible for testing of which 34 underwent germline testing (26.1%, N = 34/136). Of all prostate cancer patients in the single-center cohort undergoing germline testing (n = 173), the rate of P/LP alterations in Hispanic patients was not significantly different compared to NHW patients (14.7% vs. 12.2%, p = 0.77). The rate of VUS in Hispanic patients was significantly higher than that of NHW patients (20.6% vs. 7.2%, p = 0.047). CONCLUSION: The P/LP germline alteration rate in our cohorts was similar between Hispanic and NHW men. The rate of VUS was significantly higher in Hispanic men, a consequence of undertesting in minority populations. These data support that Hispanic men with prostate cancer should be screened for germline testing similar to NHW men.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Pan E, Shaya J, Madlensky L, et al. Germline alterations among Hispanic men with prostate cancer. Prostate Cancer Prostatic Dis. 2022. PMID: 35228665. doi:10.1038/s41391-022-00517-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。